A single operational hub coordinated remote interventions for 328 people across 22 U.S. sites in the RECOVER-NEURO trial, according to a report by Leigh Charvet and colleagues published in PLOS Digital Health. The authors describe the approach as feasible in this trial, which studied people with cognitive symptoms associated with long COVID. Their report examines how the trial’s interventions were organized and delivered; it does not report whether those interventions improved participants’ symptoms.
The trial used five randomized groups and delivered interventions at home over 10 weeks. These included computerized cognitive training, cognitive rehabilitation through telehealth, and cognitive training combined with active or sham transcranial direct current stimulation (tDCS). A fifth group used computer-based puzzles and games as an active comparator. Local sites handled recruitment, consent and clinical assessments. A hub at NYU Langone Health coordinated study kits, device programming, participant onboarding, remote supervision, adherence monitoring and equipment recovery.
The hub supported up to 168 participants at once, the report says. It contacted 327 of the 328 participants after randomization and started intervention an average of 13.5 days after first contact. Of the 328 randomized participants, 320 completed at least one intervention session. Across those participants, the average was 44 sessions over about 69 days. The hub also recovered 96.9% of the 324 study kits that were shipped.
Adherence looked high under the report’s week-by-week measure: 260 of the 320 participants who started an intervention, or 81.3%, had no assessed week below 80% of scheduled sessions. The paper also tested a different, cumulative measure: 290 participants (90.6%) completed at least 80% of all 50 prescribed sessions. Those figures use different definitions, so they should not be read as interchangeable estimates. The difference illustrates how the choice of adherence measure can affect a trial’s summary of participation.
The authors argue that central coordination can help organize several kinds of remote intervention across many trial sites. The operational details matter because a home-based study still requires equipment preparation and shipping, participant training, technical support and ways to monitor sessions. In this trial, participants without reliable home internet could receive a mobile hotspot and prepaid data. The report therefore describes a remote model supported by dedicated staff and resources, rather than a setup that removes logistical demands.
The findings have important limits. This was a descriptive analysis of one trial, not a direct comparison of centralized delivery with site-by-site delivery. The authors did not formally evaluate intervention fidelity or differences in implementation between sites. Nor did they measure costs, staff effort or how performance would change with more participants. The reported peak of 168 active participants shows the workload this hub handled in this study; it does not establish how large another hub could grow or whether the approach would work as well in other populations or trials.
The article focuses on operational feasibility. The trial’s primary clinical outcomes were reported elsewhere, and this analysis does not establish treatment effectiveness or clinical benefit. Charvet and colleagues say further work should assess staffing, resource use, cost and performance across different trial settings before the model’s scalability can be determined.